Form 8-K - Current report:
SEC Accession No. 0001628280-24-033281
Filing Date
2024-07-29
Accepted
2024-07-29 16:10:07
Documents
14
Period of Report
2024-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cort-20240729.htm   iXBRL 8-K 25398
2 EX-99.1 exhibit991pressrelease07-2.htm EX-99.1 79806
  Complete submission text file 0001628280-24-033281.txt   238558

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cort-20240729.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cort-20240729_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cort-20240729_pre.xml EX-101.PRE 12520
16 EXTRACTED XBRL INSTANCE DOCUMENT cort-20240729_htm.xml XML 2721
Mailing Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025
Business Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

EIN.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50679 | Film No.: 241152440
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)